FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatment

benzinga.com/news/fda/25/07/46319441/fda-approves-new-dosing-schedule-for-eli-lillys-kisunla-in-alzheimers-treatment

The U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Eli Lilly and Co.’s (NYSE:LLY) Kisunla (donanemab-azbt) once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer’s disease (AD). The FDA…

This story appeared on benzinga.com, 2025-07-09 13:49:19.
The Entire Business World on a Single Page. Free to Use →